Alert detail
LCD L33438: Octreotide Acetate for Injectable Suspension (Sandostatin® LAR Depot) — Palmetto GBA
What changed
Palmetto GBA Final LCD: Sandostatin LAR Depot coverage criteria, Part B.
Who’s affected: Endocrinology billing teams · Effective: July 18, 2024
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 6 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.